Metabolic syndrome in type-2 diabetics: an update on the silent epidemic

被引:0
|
作者
Tariq, Mohammad [1 ]
Hadi, Abdul [1 ]
Rahman, Sadeeq Ur [1 ]
机构
[1] Med B Ward Khyber Teaching Hosp, Dept Med, Peshawar, Pakistan
来源
RAWAL MEDICAL JOURNAL | 2010年 / 35卷 / 02期
关键词
Metabolic syndrome; Type-2; diabetes; obesity; hyperlipidemia;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine frequency of metabolic syndrome in patients with type-2 diabetes. Methods This was a cross sectional study was conducted in Khyber Teaching Hospital, Peshawar and during an eight months period, 200 adult type-2 diabetics were evaluated for the presence of metabolic syndrome. ATP-III criteria was used for its frequency. Result Of 200 patients, 154 (77%) had metabolic syndrome. Out of these154 patients, 92 (59.7) were female and 62 (40.2%) were male. Ninety seven (62.98%) patients were between the age group 41 to 60 years. In 68 (44.15%) patients, all the five risk factors for the metabolic syndrome were present. However, in 57 (37.01%) patients only 3 risk factors were present. Abdominal obesity was present in 80 (51.94%) female and in 43 (27.92%) male patients. However, 68 (44.15%) female and 49 (31.81%) males had low HDL levels. Fifty six (36.36%) females and 41 (26.62%) males had elevated levels of triglycerides. Hypertension was present in 82 (53.24%) females and 48 (31.16%) males. Conclusion This study showed a very high prevalence of the metabolic syndrome in type 2 diabetic population. Females were more affected than males in all respects.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] BIOAVAILABILITY, PHARMACOKINETICS AND EFFECTS OF GLIPIZIDE IN TYPE-2 DIABETICS
    WAHLINBOLL, E
    ALMER, LO
    MELANDER, A
    CLINICAL PHARMACOKINETICS, 1982, 7 (04) : 363 - 372
  • [32] RENAL REPLACEMENT THERAPY IN OLDER, TYPE-2 DIABETICS
    TZAMALOUKAS, AH
    HARFORD, AM
    ZAGER, PG
    AVASTHI, PS
    GIBEL, LJ
    SMITH, AY
    STERLING, WS
    KIDNEY INTERNATIONAL, 1991, 39 (01) : 193 - 193
  • [33] THE PHARMACOKINETICS OF GLIBENCLAMIDE IN TYPE-2 DIABETICS TREATED WITH ACARBOSE
    GERARD, J
    LEFEBVRE, PJ
    LUYCKX, AS
    DIABETES & METABOLISM, 1984, 10 (04): : 285 - 285
  • [34] Medications in type-2 diabetics and their association with liver fibrosis
    Siddiqui, Mohamed Tausif
    Amin, Hina
    Garg, Rajat
    Chadalavada, Pravallika
    Al-Yaman, Wael
    Lopez, Rocio
    Singh, Amandeep
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (23) : 3249 - 3259
  • [35] RENAL FINDINGS IN NEWLY DIAGNOSED TYPE-2 DIABETICS
    WIRTA, O
    PASTERNACK, A
    KIDNEY INTERNATIONAL, 1990, 37 (05) : 1381 - 1382
  • [36] Medications in type-2 diabetics and their association with liver fibrosis
    Mohamed Tausif Siddiqui
    Hina Amin
    Rajat Garg
    Pravallika Chadalavada
    Wael Al-Yaman
    Rocio Lopez
    Amandeep Singh
    World Journal of Gastroenterology, 2020, (23) : 3249 - 3259
  • [37] METABOLIC EFFECTS OF REPAGLINIDE, A NEW ORAL HYPOGLYCEMIC AGENT IN THERAPY-NAIVE TYPE-2 DIABETICS
    VANGAAL, LF
    VANACKER, KL
    DAMSBO, P
    DELEEUW, IH
    DIABETOLOGIA, 1995, 38 : A43 - A43
  • [38] Differential immunoactivation in type-2 diabetics with diabetic foot syndrome -: RANTES as a possible risk marker?
    Rose, B
    Weigelt, C
    Shin, DI
    Friese, G
    Othman, T
    Poschen, U
    Röhrig, K
    Herder, C
    Koenig, W
    Scherbaum, WA
    Martin, S
    MEDIZINISCHE KLINIK, 2006, 101 (04) : A15 - A16
  • [39] BENFLUOREX ACTION ON METABOLIC CONTROL AND INSULIN SENSITIVITY IN TYPE-2 NON-INSULIN DEPENDENT DIABETICS
    PASQUALI, R
    COLELLA, P
    CAPELLI, M
    ZANNARINI, L
    MELCHIONDA, N
    BARBARA, L
    PANMINERVA MEDICA, 1989, 31 (03) : 114 - 118
  • [40] The adipokines and inflammatory marker in young type 2 diabetics with metabolic syndrome: A pilot study
    Wen, Min-Jie
    Hsieh, Chang-Hsun
    Wu, Chung-Ze
    Hsiao, Fone-Ching
    Hsia, Te-Lin
    Hung, Yi-Jen
    Pei, Dee
    OBESITY RESEARCH & CLINICAL PRACTICE, 2013, 7 (03) : E206 - E210